<DOC>
	<DOCNO>NCT02171234</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability multiple dose regimen BIA 2-093 healthy young male volunteer</brief_summary>
	<brief_title>A Double-blind , Randomised , Placebo-controlled , Rising Multiple Dose Study Investigate Safety , Tolerability , Steady State Pharmacokinetic Profile CNS Effects BIA 2-093</brief_title>
	<detailed_description>Single centre , Phase I , double-blind , randomise , placebo-controlled study investigate 4 multiple rise oral dos BIA 2-093 4 group 8 young healthy male subject . Within group , 2 subject randomise receive placebo remain 6 subject receive BIA 2-093 . No subject member one group . The dose regimen investigate : 200 mg b.i.d . ( twice daily ) , 400 mg o.d . ( daily ; change 400 mg b.i.d . protocol amendment 1 , basis interim pharmacokinetic analysis Group 1 data ) , 800 mg o.d , 1200 mg o.d . BIA 2-093/placebo administer orally daily Days 1-8 , twice day ( 12-hour interval ) Days 1-7 final dose morning Day 8 . The multiple dose regimen investigate ascend order . Progression high dose level occur previous dose level deem investigator sponsor safe well tolerate .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Adult male age 1845 year , body mass index ( BMI ) 1928 kg/m2 . Subjects healthy determine prestudy medical history , physical examination , 12lead ECG EEG . Subjects clinical laboratory test acceptable investigator . Subjects negative HbsAg , antiHCV HIV I II test screen . Subjects negative drug abuse alcohol test screen admission . Subjects nonsmoker previous smoker smoke least 6 month . Subjects able willing give write informed consent . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity ( carbamazepine relate compound ) . Subjects history alcoholism . Subjects history drug abuse . Subjects consume 28 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) . Subjects acute infection influenza time screen and/or admission . Subjects use prescription drug within 4 week first dose . Subjects use counter medication , exclude routine vitamin include mega dose vitamin therapy , within one week dosing . Subjects use investigational drug and/or participate clinical trial within 3 month admission study . Subjects donate and/or receive blood blood product within 3 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . Subjects previously receive BIA 2093 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>BIA 2-093</keyword>
	<keyword>Eslicarbazepine acetate</keyword>
</DOC>